Potassium channel blockers or derivatives thereof for preventing, alleviating, and/or treating tissue dysfunction caused by toxic insults

A method of reducing or reversing a tissue damage, oxidation damage, scarring, or any combination thereof in a subject in need thereof,

• wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one potassium channel blocker or an analog, a racemate, a tautomer, an isomer, an enantiomer, a diastereomer, a prodrug, a pharmaceutically acceptable salt, or a derivative thereof;
• and
• the tissue damage, oxidation damage, scarring, or any combination thereof is caused by a toxic insult.

A method of restoring, improving, or enhancing at least a portion of tissue function in a subject in need thereof,

• wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one potassium channel blocker or an analog, a racemate, a tautomer, an isomer, an enantiomer, a diastereomer, a prodrug, a pharmaceutically acceptable salt, or a derivative thereof;
• and
• the tissue function was reduced by a toxic insult.

A method of restoring, improving, or enhancing myelination in a subject in need thereof,

• wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one potassium channel blocker or an analog, a racemate, a tautomer, an isomer, an enantiomer, a diastereomer, a prodrug, a pharmaceutically acceptable salt, or a derivative thereof, and
• the myelination was reduced or modulated by a toxic insult.

A method of preventing, alleviating, or treating a mitochondrial damage or mitochondrial dysfunction caused by a toxic insult in a subject in need thereof,

• wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one potassium channel blocker or an analog, a racemate, a tautomer, an isomer, an enantiomer, a diastereomer, a prodrug, a pharmaceutically acceptable salt, or a derivative thereof.

A method of preventing, alleviating, or treating an axonal damage or axonal dysfunction caused by a toxic insult in a subject in need thereof,

• wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one potassium channel blocker or an analog, a racemate, a tautomer, an isomer, an enantiomer, a diastereomer, a prodrug, a pharmaceutically acceptable salt, or a derivative thereof.

A method of preventing, alleviating, or treating at least one gait abnormality caused by a toxic insult in a subject in need thereof,

• wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one potassium channel blocker or an analog, a racemate, a tautomer, an isomer, an enantiomer, a diastereomer, a prodrug, a pharmaceutically acceptable salt, or a derivative thereof.

A method of enhancing tissue regeneration, cell survival, or a combination thereof in a subject in need thereof,

• wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one potassium channel blocker or an analog, a racemate, a tautomer, an isomer, an enantiomer, a diastereomer, a prodrug, a pharmaceutically acceptable salt, or a derivative thereof, and
• the subject was exposed to at least one toxic insult.

A method of preventing, alleviating, or treating a chemotherapy-induced peripheral neuropathy (CIPN) in a subject in need thereof,

• wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one potassium channel blocker or an analog, a racemate, a tautomer, an isomer, an enantiomer, a diastereomer, a prodrug, a pharmaceutically acceptable salt, or a derivative thereof.